




# ASCO GU 2026

## Güncelleme



19-20 Haziran 2026

Anemon Otel, Samsun


13:00-13:15	Açılış Dr. Ender Özden Dr. Şaban Sarıkaya, Dr. Murat Danacı
13:30-15:30	1. Oturum Non-muscle-invasive Bladder Cancer Management In Transition: Integrating Emerging Evidence Into Practice Oturum Başkanları: Dr. Kamil Çam, Dr. Y. Kâmil Yakupoğlu
13:30-13:50	Optimizing Surgical Management Of Non-muscle-invasive Bladder Cancer Dr. Saadettin Eskiçorapçı
13:50-14:10	Optimizing Radiation Therapy For Non-muscle-invasive Bladder Cancer Dr. Nilgün Okumuş
	<b>Karşıtlık</b>
14:10-14:25	For: Bacillus Calmette-guérin Plus Immune Checkpoint Inhibition For High-risk Non-muscle-invasive Bladder Cancer Dr. Evren Süer
14:25-14:40	Against: Bacillus Calmette-guérin Plus Immune Checkpoint Inhibition For High-risk Non-muscle-invasive Bladder Cancer Dr. Deniz Bolat



# ASCO GU 2026

## Güncelleme

19-20 Haziran 2026  
Anemon Otel, Samsun




14:40-15:20	Seçilmiş Bildiriler
14:40 - 15:00	<b>Dr. Murat Gülşen</b>
	Abstract Lba630: Neoadjuvant And Adjuvant Enfortumab Vedotin (ev) Plus Pembrolizumab (pembro) For Participants With Muscle-invasive Bladder Cancer (mIBC) Who Are Eligible For Cisplatin: Randomized, Open-label, Phase 3 Keynote-b15 Study.
	Abstract 638: Pathological Outcomes And Disease-free Survival (dfs) In Keynote-905: Neoadjuvant And Adjuvant (neoadj) Enfortumab Vedotin (ev) Plus Pembrolizumab (pembro) In Participants (pts) With Muscle-invasive Bladder Cancer (mIBC) Who Are Cisplatin-ineligible.
	Abstract 737: Phase 2 Trial Of Pembrolizumab (p) With Responseguided Bladder-sparing In Patients With Muscle-invasive Bladder Cancer (mIBC; Hcrn Gu 20-444).
	Abstract Lba629: Swog S1602: A Phase III Randomized Trial To Evaluate Bcg Strain Differences And Priming With Intradermal Bcg Before Intravesical Therapy For Bcg-naïve High-grade Nonmuscle Invasive Bladder Cancer (nct #03091660).
	Abstract Lba637: Induction Ipilimumab Plus Nivolumab Followed By Consolidating Chemoradiotherapy As Bladder-sparing Treatment In Stage I/III Urothelial Carcinoma Of The Bladder: The Phase 2 Indi-blade Trial
15:00 - 15:20	<b>Dr. Emre Yekedüz</b>
	Abstract Lba632: Circulating Tumor Dna (ctdna) To Guide Response-adapted Bladder Preservation In Muscle Invasive Bladder Cancer (mIBC): Integrated Analysis Of The Retain Trials.
	Abstract 633: Circulating Tumor (ct)dna-guided Adjuvant Atezolizumab (atezo) In Muscle-invasive Bladder Cancer (mIBC): Exploratory Analysis Of Ctdna Dynamics In The Invigor011 Trial.
	Abstract 634: Keymaker-u04 Substudy 04b: First-line (1l) Enfortumab Vedotin (ev) Plus Pembrolizumab (pembro)-based Immune Checkpoint Inhibitor (ICI) Combinations For Advanced Urothelial Cancer (uc).
	Abstract 636: Urinary Tumor Dna (utdna) And Circulating Tumor Dna (ctdna) In Patients (pts) With Muscle-invasive Bladder Cancer (mIBC) Who Received Perioperative Durvalumab (d) In Niagara.
15:20-15:30	Soru Cevap
15:30-16:00	Kahve Arası



# ASCO GU 2026

## Güncelleme

19-20 Haziran 2026  
Anemon Otel, Samsun



16:00-17:15	<b>2. Oturum</b> <b>Multidisciplinary Tumor Board: Innovative Approaches To Bladder Preservation</b> <b>Moderatör: Dr. Sümer Baltacı</b>
	<b>Dr. Pervin Hürmüz, Dr. Yasemin Kemal, Dr. Güven Aslan, Dr. Murat Danacı</b>

### 20 Haziran Cumartesi


09:00-10:15	<b>1. Oturum</b> <b>Innovations In Kidney Cancer In 2026: Diagnostics, Novel Targets, And Trial Design</b> <b>Oturum Başkanları: Dr. Sinan Sözen- Dr. Cenk Yücel Bilen</b>
09:00-09:15	Imaging For Renal Cell Carcinoma: Current State Of The Art <b>Dr. Cemil Aydın</b>
09:15-09:30	Emerging Tools In Imaging In Renal Cell Carcinoma <b>Dr. Mehmet Mercimek</b>
09:30-09:50	Novel Targets In Kidney Cancer <b>Dr. Mustafa Karaağaç</b>
	<b>Seçilmiş Bildiriler</b>
09:50 - 10:05	<b>Dr. İlker Akarken</b>
	Abstract 420: Patient-reported Outcomes In Resected Renal Cell Carcinoma: Active Monitoring Vs. Durvalumab And Tremelimumab In The Rampart Trial.
	Abstract 421: Ultra-sensitive Whole-genome Sequencing-based Molecular Residual Disease Detection In Resectable Renal Cell Carcinoma: Preliminary Results From The Monstar-screen-3 Study
	Abstract 537: Circulating KIm-1 And Ctdna As Prognostic Markers In Oligometastatic Clear Cell Renal Cell Carcinoma (ccrcc): The K-compass Model.
10:05-10:15	<b>Soru Cevap</b>
10:15-10:45	<b>Kahve Arası</b>



# ASCO GU 2026

## Güncelleme

19-20 Haziran 2026  
Anemon Otel, Samsun




10:45-12:15	<b>2. Oturum</b> <b>Multidisciplinary Tumor Board: Challenges And Opportunities In Treating Patients With Advanced Kidney Cancer</b> <b>Moderatör: Dr. Volkan İzol</b>
	<b>Dr. Oktay Üçer, Dr. Yüksel Ürün, Dr. Selim Nural, Dr. Volkan İzol, Dr. H. Cem Önal</b>
12:15-13:00	<b>Öğle Yemeği</b>
13:00-15:20	<b>3. Oturum</b> <b>Balancing Cure And Quality: Navigating Functional Outcomes In Localized Prostate Cancer</b> <b>Oturum Başkanları: Dr. Levent Türkeri - Dr. Nalan Alan Selçuk</b>
13:00-13:15	Minimizing Harm: Surgical Approaches To Preserve Continence And Sexual Function <b>Dr. Bahadır Şahin</b>
13:15-13:30	Precision Matters: How Radiation Choices Shape Quality Of Life <b>Dr. H. Cem Önal</b>
	<b>Treatment Selection, Response Assessment, And Monitoring Across The Spectrum Of Advanced Prostate Cancer</b>
13:30-13:50	Making Sense Of Many Options: Metastatic Hormone-sensitive Prostate Cancer Treatment Selection <b>Dr. Mustafa Erman</b>
13:50-14:10	Evaluation And Definition Of Response And Progression From Trials To Clinical Practice <b>Dr. Yüksel Ürün</b>
14:10-14:30	New Treatment Options For Patients With Castrate-resistant Prostate Cancer <b>Dr. Yasemin Kemal</b>
14:30-14:45	<b>Soru Cevap</b>



# ASCO GU 2026

## Güncelleme

19-20 Haziran 2026  
Anemon Otel, Samsun



14:45-15:00	Seçilmiş Bildiriler
14:45 - 15:05	<b>Dr. Serhat Çetin</b> Abstract Lba307: Androgen Deprivation Therapy And Radiotherapy With Or Without Cabazitaxel In Very-high Risk Localized Prostate Cancer: First Results Of The Peace-2 Randomized Phase III Trial. Abstract 309: Genomic Alterations And Pathologic Responses To Neoadjuvant Androgen Receptor Pathway Inhibitor (arpi) Doublets Vs Docetaxel Triplets In The Genomic Umbrella Neoadjuvant Study (guns). Abstract 305: Hormone Therapy Use And Duration With Postoperative Radiotherapy For Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis. Abstract 16: Overall Survival From The Phase 2 Trial Of Abiraterone, Olaparib, Or Abiraterone + Olaparib In First-line Metastatic Castration-resistant Prostate Cancer (mcrpc) With Dna Repair Defects (brcaaway).
15:05 - 15:20	<b>Dr. Nazım Coşkun</b> Abstract 15: Final Overall Survival Results From The Eortc 1333/ Peace-3 Trial: Enzalutamide With Or Without Radium-223 In Metastatic Castration-resistant Prostate Cancer. Abstract 18: Health-related Quality Of Life, Pain, And Symptomatic Skeletal Events In The Phase 3 Psmadition Study Of [177lu] Lu-psma-617 (177lu-psma-617) Combined With Adt And Arpi In Patients With Psma-positive Mhspc Abstract 19: First-in-human Assessment Of Actinium-225- Prostate-specific Membrane Antigen (225ac-psma)-trillium (bay 3563254) In Mcrpc: Dose-escalation Results Of The Phase 1 Pantha Study.
15:20 - 15:50	Kahve Arası
15:50 - 17:05	<b>4. Oturum</b> <b>Multidisciplinary Tumor Board: From Imaging To Molecular Insights—tailoring Therapy Intensity In Localized/locally Advanced Prostate Cancer</b> <b>Moderatör: Dr. İlker Tinay</b> <b>Dr. İlker Tinay, Dr. Pervin Hürmüz, Dr. İlkey Çamlıdağ, Dr. Mustafa Erman, Dr. Serdar Çelik</b>
	Kapanış